Click here to get full coverage on Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML - AJMC

Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML  AJMC

Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML - AJMC

Click here to get full coverage on Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ...  Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

Click here to get full coverage on ALLO Fiber Blames New BEAD Requirements for Layoffs - Broadband Breakfast

ALLO Fiber Blames New BEAD Requirements for Layoffs  Broadband Breakfast

ALLO Fiber Blames New BEAD Requirements for Layoffs - Broadband Breakfast

Click here to get full coverage on ALLO Fiber confirms dozens of employee layoffs across Nebraska - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

ALLO Fiber confirms dozens of employee layoffs across Nebraska  KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

ALLO Fiber confirms dozens of employee layoffs across Nebraska - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Click here to get full coverage on Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha

Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO)  Seeking Alpha

Allogene Therapeutics: Important Catalysts Guided For Early 2026 (NASDAQ:ALLO) - Seeking Alpha

Click here to get full coverage on Allo seeks 'voluntary resignations' amid need for more funding - Light Reading

Allo seeks 'voluntary resignations' amid need for more funding  Light Reading

Allo seeks 'voluntary resignations' amid need for more funding - Light Reading

Click here to get full coverage on ALLO Communications Offers Voluntary Layoff Program Amid Funding Strain - klin.com

ALLO Communications Offers Voluntary Layoff Program Amid Funding Strain  klin.com

ALLO Communications Offers Voluntary Layoff Program Amid Funding Strain - klin.com

Click here to get full coverage on Joyce Allo Rodrigue Obituary May 5, 2025 - Mothe Funeral Homes, LLC

Joyce Allo Rodrigue Obituary May 5, 2025  Mothe Funeral Homes, LLC

Joyce Allo Rodrigue Obituary May 5, 2025 - Mothe Funeral Homes, LLC

Click here to get full coverage on ALLO COMMUNICATIONS - Ad from 2025-08-09 - Fremont Tribune

ALLO COMMUNICATIONS - Ad from 2025-08-09  Fremont Tribune

ALLO COMMUNICATIONS - Ad from 2025-08-09 - Fremont Tribune

Click here to get full coverage on $ALLO stock is up 18% today. Here's what we see in our data. - Quiver Quantitative

$ALLO stock is up 18% today. Here's what we see in our data.  Quiver Quantitative

$ALLO stock is up 18% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - TradingView

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus  TradingView

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus - TradingView

Click here to get full coverage on ALLO Fiber completes network construction in Greeley - Broadband Communities

ALLO Fiber completes network construction in Greeley  Broadband Communities

ALLO Fiber completes network construction in Greeley - Broadband Communities

Click here to get full coverage on Eliminating Barriers to Allo-HCT When Treating AML - Hematology Advisor

Eliminating Barriers to Allo-HCT When Treating AML  Hematology Advisor

Eliminating Barriers to Allo-HCT When Treating AML - Hematology Advisor

Click here to get full coverage on ALLO Fiber Confirms Layoffs in Nebraska and Beyond - The Sidney Sun-Telegraph

ALLO Fiber Confirms Layoffs in Nebraska and Beyond  The Sidney Sun-Telegraph

ALLO Fiber Confirms Layoffs in Nebraska and Beyond - The Sidney Sun-Telegraph

Click here to get full coverage on ASCO 2025: ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results from the Phase 1 TRAVERSE Study - UroToday

ASCO 2025: ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results from the Phase 1 TRAVERSE Study  UroToday

ASCO 2025: ALLO-316 in Advanced Clear Cell Renal Cell Carcinoma: Updated Results from the Phase 1 TRAVERSE Study - UroToday

Click here to get full coverage on Allogene Therapeutics' ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News

Allogene Therapeutics' ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma  CRISPR Medicine News

Allogene Therapeutics' ALLO-316 Shows Durable Responses in Advanced Renal Cell Carcinoma - CRISPR Medicine News

Click here to get full coverage on ALLO Fiber Cutting Staff Fast to Fight Cash Burn - Broadband Breakfast

ALLO Fiber Cutting Staff Fast to Fight Cash Burn  Broadband Breakfast

ALLO Fiber Cutting Staff Fast to Fight Cash Burn - Broadband Breakfast

Click here to get full coverage on Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect  Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance

Click here to get full coverage on ALLO Fiber brings 2-Gig Internet speeds to Lincoln - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

ALLO Fiber brings 2-Gig Internet speeds to Lincoln  KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

ALLO Fiber brings 2-Gig Internet speeds to Lincoln - KOLN | Nebraska Local News, Weather, Sports | Lincoln, NE

Click here to get full coverage on Allo lays off 9% of staff after 'voluntary resignation' offer - Light Reading

Allo lays off 9% of staff after 'voluntary resignation' offer  Light Reading

Allo lays off 9% of staff after 'voluntary resignation' offer - Light Reading

Click here to get full coverage on Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC - Targeted Oncology

Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC  Targeted Oncology

Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC - Targeted Oncology

Click here to get full coverage on Around 70 ALLO employees laid off across Nebraska - KLKN-TV

Around 70 ALLO employees laid off across Nebraska  KLKN-TV

Around 70 ALLO employees laid off across Nebraska - KLKN-TV

Click here to get full coverage on Allo & Piacenza Surge NJCU Past Rutgers-Newark, 9-2 - New Jersey City University Athletics

Allo & Piacenza Surge NJCU Past Rutgers-Newark, 9-2  New Jersey City University Athletics

Allo & Piacenza Surge NJCU Past Rutgers-Newark, 9-2 - New Jersey City University Athletics

Click here to get full coverage on Garrett Allo Earns Second-Straight NJAC All-Conference Nod - New Jersey City University Athletics

Garrett Allo Earns Second-Straight NJAC All-Conference Nod  New Jersey City University Athletics

Garrett Allo Earns Second-Straight NJAC All-Conference Nod - New Jersey City University Athletics

Click here to get full coverage on Andy Allo to Lead Alcon’s ‘The Eagles of Newark’ Limited Series From Showrunner Mike Flynn (EXCLUSIVE) - Variety

Andy Allo to Lead Alcon’s ‘The Eagles of Newark’ Limited Series From Showrunner Mike Flynn (EXCLUSIVE)  Variety

Andy Allo to Lead Alcon’s ‘The Eagles of Newark’ Limited Series From Showrunner Mike Flynn (EXCLUSIVE) - Variety

Click here to get full coverage on New Analyst Forecast: $ALLO Given 'Neutral' Rating - Quiver Quantitative

New Analyst Forecast: $ALLO Given 'Neutral' Rating  Quiver Quantitative

New Analyst Forecast: $ALLO Given 'Neutral' Rating - Quiver Quantitative

Click here to get full coverage on All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy  Yahoo Finance

All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to Buy - Yahoo Finance

Click here to get full coverage on ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest

ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies  AInvest

ALPHA3 Trial Update: Contradictions in Enrollment, Data Expectations, and Lymphodepletion Strategies - AInvest

Click here to get full coverage on Allo Corbett - View Obituary & Service Information - Posey Funeral Directors

Allo Corbett - View Obituary & Service Information  Posey Funeral Directors

Allo Corbett - View Obituary & Service Information - Posey Funeral Directors

Click here to get full coverage on Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive®

Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications  CGTLive®

Allogene Therapeutics’ ALLO-329 Cleared by FDA for Phase 1 Clinical Trial in Rheumatology Indications - CGTLive®

Click here to get full coverage on Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis - ScienceDirect.com

Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis  ScienceDirect.com

Allo-lithocholic acid, a microbiome derived secondary bile acid, attenuates liver fibrosis - ScienceDirect.com

Click here to get full coverage on ALLO Fiber cleared to resume installation following brief stop work order by City | Sierra Vista - Sierra Vista Herald

ALLO Fiber cleared to resume installation following brief stop work order by City | Sierra Vista  Sierra Vista Herald

ALLO Fiber cleared to resume installation following brief stop work order by City | Sierra Vista - Sierra Vista Herald

Click here to get full coverage on Trump Organization, Allo Fiber leap into the mobile fray - Light Reading

Trump Organization, Allo Fiber leap into the mobile fray  Light Reading

Trump Organization, Allo Fiber leap into the mobile fray - Light Reading

Click here to get full coverage on Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030?  Yahoo Finance

Is Allogene Therapeutics, Inc. (ALLO) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance

Click here to get full coverage on Allogene Therapeutics’ ALLO-329 Receives FDA Fast Track Designation for Three Autoimmune Conditions, Including Active Refractory Moderate-to-Severe Systemic Lupus Erythematosus - Lupus Foundation of America

Allogene Therapeutics’ ALLO-329 Receives FDA Fast Track Designation for Three Autoimmune Conditions, Including Active Refractory Moderate-to-Severe Systemic Lupus Erythematosus  Lupus Foundation of America

Allogene Therapeutics’ ALLO-329 Receives FDA Fast Track Designation for Three Autoimmune Conditions, Including Active Refractory Moderate-to-Severe Systemic Lupus Erythematosus - Lupus Foundation of America

Click here to get full coverage on Dr Srour Highlights ALLO-316 Phase 1 Success in Advanced ccRCC - Targeted Oncology

Dr Srour Highlights ALLO-316 Phase 1 Success in Advanced ccRCC  Targeted Oncology

Dr Srour Highlights ALLO-316 Phase 1 Success in Advanced ccRCC - Targeted Oncology

Click here to get full coverage on Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?  Yahoo Finance

Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML - Nature

Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML  Nature

Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML - Nature

Click here to get full coverage on Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...  Yahoo Finance

Allogene Therapeutics Inc (ALLO) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Click here to get full coverage on Allo Fiber Comes to Joplin - FourStatesHomepage.com

Allo Fiber Comes to Joplin  FourStatesHomepage.com

Allo Fiber Comes to Joplin - FourStatesHomepage.com

Click here to get full coverage on Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures  simplywall.st

Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) latest 17% decline adds to one-year losses, institutional investors may consider drastic measures - simplywall.st

Click here to get full coverage on Allo Fiber launches downtown Joplin store for citywide network - FourStatesHomepage.com

Allo Fiber launches downtown Joplin store for citywide network  FourStatesHomepage.com

Allo Fiber launches downtown Joplin store for citywide network - FourStatesHomepage.com

Click here to get full coverage on Allo-HSCT Consolidation Appears Beneficial for Older AML Patients - Hematology Advisor

Allo-HSCT Consolidation Appears Beneficial for Older AML Patients  Hematology Advisor

Allo-HSCT Consolidation Appears Beneficial for Older AML Patients - Hematology Advisor

Click here to get full coverage on Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) | Blood Cancer Jour - Nature

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) | Blood Cancer Jour  Nature

Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) | Blood Cancer Jour - Nature

Click here to get full coverage on Allo Fiber completes network in Greeley - BizWest

Allo Fiber completes network in Greeley  BizWest

Allo Fiber completes network in Greeley - BizWest

Click here to get full coverage on Andy Allo and Allegra Edwards Talk Upload Season 4, Cast Tattoos, and Favorite Moments - Tell-Tale TV

Andy Allo and Allegra Edwards Talk Upload Season 4, Cast Tattoos, and Favorite Moments  Tell-Tale TV

Andy Allo and Allegra Edwards Talk Upload Season 4, Cast Tattoos, and Favorite Moments - Tell-Tale TV

Click here to get full coverage on Album Review: Allo Darlin’ – Bright Nights - mxdwn Music

Album Review: Allo Darlin’ – Bright Nights  mxdwn Music

Album Review: Allo Darlin’ – Bright Nights - mxdwn Music

Click here to get full coverage on Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner  Yahoo Finance

Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Click here to get full coverage on ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma - OncLive

ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma  OncLive

ALLO-316 Produces Responses in Heavily Pretreated Clear Cell Renal Carcinoma - OncLive

Click here to get full coverage on Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive®

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths  CGTLive®

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive®

Click here to get full coverage on Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications  CGTLive®

Allogene Therapeutics’ ALLO-329 Snags FDA Fast Track Designations for 3 Rheumatology Indications - CGTLive®

Click here to get full coverage on Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases | Blood Cancer Journal - Nature

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases | Blood Cancer Journal  Nature

Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases | Blood Cancer Journal - Nature

Click here to get full coverage on Nelnet Gains $175M from ALLO Holdings Redemption - TipRanks

Nelnet Gains $175M from ALLO Holdings Redemption  TipRanks

Nelnet Gains $175M from ALLO Holdings Redemption - TipRanks

Click here to get full coverage on Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial - Lupus Foundation of America

Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial  Lupus Foundation of America

Allogene Therapeutics’ ALLO-329 Received FDA IND Clearance for Autoimmune Disease Trial - Lupus Foundation of America

Click here to get full coverage on TP53 Alteration Negatively Impacts Allo-HSCT Outcomes in MDS - Hematology Advisor

TP53 Alteration Negatively Impacts Allo-HSCT Outcomes in MDS  Hematology Advisor

TP53 Alteration Negatively Impacts Allo-HSCT Outcomes in MDS - Hematology Advisor

Click here to get full coverage on Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients - OncLive

Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients  OncLive

Investigational Microbiotherapy MaaT033 Is Safe in Allo-HSCT Recipients - OncLive

Click here to get full coverage on Allo Fiber sets up shop in downtown Joplin - FourStatesHomepage.com

Allo Fiber sets up shop in downtown Joplin  FourStatesHomepage.com

Allo Fiber sets up shop in downtown Joplin - FourStatesHomepage.com

Click here to get full coverage on ALLO Fiber Agrees to Net Neutrality in Network Lease Deal with Boulder, Colo - Broadband Breakfast

ALLO Fiber Agrees to Net Neutrality in Network Lease Deal with Boulder, Colo  Broadband Breakfast

ALLO Fiber Agrees to Net Neutrality in Network Lease Deal with Boulder, Colo - Broadband Breakfast

Click here to get full coverage on Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News

Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial  CRISPR Medicine News

Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News

Click here to get full coverage on THE POWER OF ALLO'S ALL-FIBER NETWORK COMING TO FLAGSTAFF, ARIZONA - PR Newswire

THE POWER OF ALLO'S ALL-FIBER NETWORK COMING TO FLAGSTAFF, ARIZONA  PR Newswire

THE POWER OF ALLO'S ALL-FIBER NETWORK COMING TO FLAGSTAFF, ARIZONA - PR Newswire

Click here to get full coverage on Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial | Circulation - American Heart Association Journals

Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial | Circulation  American Heart Association Journals

Preventing Allogeneic Stem Cell Transplant–Related Cardiovascular Dysfunction: ALLO-Active Trial | Circulation - American Heart Association Journals

Click here to get full coverage on The highly allo-autopolyploid modern sugarcane genome and very recent allopolyploidization in Saccharum - Nature

The highly allo-autopolyploid modern sugarcane genome and very recent allopolyploidization in Saccharum  Nature

The highly allo-autopolyploid modern sugarcane genome and very recent allopolyploidization in Saccharum - Nature

Click here to get full coverage on Newton County Commission approves ALLO broadband agreement - KOAM News Now

Newton County Commission approves ALLO broadband agreement  KOAM News Now

Newton County Commission approves ALLO broadband agreement - KOAM News Now

Click here to get full coverage on ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC - OncLive

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC  OncLive

ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC - OncLive

Click here to get full coverage on Allo Darlin’ Announce First New Album In 11 Years Bright Nights : Hear “My Love Will Bring You Home” - Stereogum

Allo Darlin’ Announce First New Album In 11 Years Bright Nights : Hear “My Love Will Bring You Home”  Stereogum

Allo Darlin’ Announce First New Album In 11 Years Bright Nights : Hear “My Love Will Bring You Home” - Stereogum

Click here to get full coverage on $9M deal struck for fiber internet in Boulder - The Business Journals

$9M deal struck for fiber internet in Boulder  The Business Journals

$9M deal struck for fiber internet in Boulder - The Business Journals

Click here to get full coverage on Allo Darlin’ Share First New Song Nine Years “Tricky Questions” - Stereogum

Allo Darlin’ Share First New Song Nine Years “Tricky Questions”  Stereogum

Allogene Therapeutics Inc (ALLO)

Price Chart

Key Statistics

Technicals

About ALLO

Latest News

Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML - AJMC

Allogene Therapeutics Inc (ALLO) Q2 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance

ALLO Fiber Blames New BEAD Requirements for Layoffs - Broadband Breakfast

Advanced Charts

Top Gainers

Top Losers